文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

代谢组学改变与慢性肾脏病病因相关

Metabolomic Alterations Associated with Cause of CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-09-28

该研究基于MDRD试验,对血清样本进行非靶向代谢组学检测,发现7种代谢物与CKD病因相关,其中5种在独立样本中验证。与其它病因相比,多囊肾病中这些代谢物水平较高,肾小球疾病中较低。代谢组学分析有助于区分CKD病因。

要点

  • 7种代谢物与CKD病因相关,5种在外部样本中验证
  • 多囊肾病中代谢物水平较高,肾小球疾病中较低
  • 代谢组学可能为CKD病因鉴别提供线索

核心结论

  • 代谢组学分析识别出几种与CKD病因密切相关的代谢物。

研究设计与样本

  • 基于MDRD随机对照试验,对血清样本使用非靶向反相超高效液相色谱串联质谱定量代谢物(n=687)。
  • 发现阶段在Study B(低GFR,n=166)进行,验证阶段在Study A(较高GFR,n=423)进行。
  • MDRD总体平均年龄51岁,61%为男性。

主要发现

  • 发现阶段7种代谢物与CKD病因相关(P<0.0008),包括16-羟基棕榈酸、犬尿喹啉酸等。
  • 5种代谢物在Study A中验证(P<0.007),多囊肾病中水平较高,肾小球疾病中较低。
  • Study B中多囊肾病占29%、肾小球疾病28%、其他病因43%;Study A中分别为28%、24%、48%。

关键数值与推荐

  • 代谢物关联分析校正了人口学、随机分组、BMI、降压药、实测GFR、对数尿蛋白和估计蛋白摄入。
  • 发现阶段多重比较校正后P<0.0008,验证阶段P<0.007。

临床怎么用

  • 血清代谢物谱可能辅助鉴别CKD病因,尤其是多囊肾病与肾小球疾病。

局限性

  • 研究基于MDRD试验人群,结果外推需谨慎。
  • 发现与验证样本量有限,部分代谢物未验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Causes of CKD differ in prognosis and treatment. Metabolomic indicators of CKD cause may provide clues regarding the different physiologic processes underlying CKD development and progression. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Metabolites were quantified from serum samples of participants in the Modification of Diet in Renal Disease (MDRD) Study, a randomized controlled trial of dietary protein restriction and BP control, using untargeted reverse phase ultraperformance liquid chromatography tandem mass spectrometry quantification. Known, nondrug metabolites (n=687) were log-transformed and analyzed to discover associations with CKD cause (polycystic kidney disease, glomerular disease, and other cause). Discovery was performed in Study B, a substudy of MDRD with low GFR (n=166), and replication was performed in Study A, a substudy of MDRD with higher GFR (n=423). RESULTS: Overall in MDRD, average participant age was 51 years and 61% were men. In the discovery study (Study B), 29% of participants had polycystic kidney disease, 28% had glomerular disease, and 43% had CKD of another cause; in the replication study (Study A), the percentages were 28%, 24%, and 48%, respectively. In the discovery analysis, adjusted for demographics, randomization group, body mass index, hypertensive medications, measured GFR, log-transformed proteinuria, and estimated protein intake, seven metabolites (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, hippurate, homocitrulline, and 1,5-anhydroglucitol) were associated with CKD cause after correction for multiple comparisons (P<0.0008). Five of these metabolite associations (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, and hippurate) were replicated in Study A (P<0.007), with all replicated metabolites exhibiting higher levels in polycystic kidney disease and lower levels in glomerular disease compared with CKD of other causes. CONCLUSIONS: Metabolomic profiling identified several metabolites strongly associated with cause of CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Grams ME, Tin A, Rebholz CM, et al. Metabolomic Alterations Associated with Cause of CKD. Clin J Am Soc Nephrol. 2017. PMID: 28971980. doi:10.2215/CJN.02560317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。